Online Presentation       Release Date: Monday, December 17, 2018     Expiration Date: Tuesday, December 17, 2019

The management of patients with pulmonary arterial hypertension (PAH) has undergone a vast transformation over the past decade with an improved understanding of the disease and an expansion of treatment options. Though patient survival was once considered the main treatment goal of PAH, outcomes can now include improved hemodynamics, prevention of clinical worsening, and improved quality of life. A key challenge in improving outcomes is early identification of the disease and initiating aggressive treatment. Greater emphasis is also being placed in identifying prognostic factors and assessing patient risk in order to tailor therapy accordingly.

Treatment options for PAH are complex and dosing regimens must be specifically followed to avoid serious safety consequences. Research in the pathophysiology of PAH has revealed three major pathways involved in the disease process: the endothelin, nitric oxide, and prostacyclin pathways. Over the past two decades, several treatment options have become available that target these pathways that allow clinicians flexibility is designing optimal regimens. The recent availability of subcutaneous and oral medications allows greater ease of dosing and can expand the prescriber base beyond PAH specialists. Furthermore, the use of combination therapy is increasingly becoming standard of care as more and more clinical trial results support the use of this approach. However, treatment must be individualized based on disease severity and patient factors. Clinicians responsible for the management of patients with PAH must have a thorough understanding of PAH medications, including transitioning care between hospital and home, in order to safely and effectively manage the disease.



This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small healthcare systems, outpatient clinics, managed care organizations, long-term care facilities, and academia. This program will target pharmacists who are responsible for the safe and effective use of medications utilized for the treatment of patients with PAH.


Upon completing this activity, participants will be able to:

  • Utilize the latest evidence-based treatment recommendation to guide therapeutic approaches for pulmonary arterial hypertension (PAH) based on disease severity and prognostic factors
  • Evaluate current PAH medications, as monotherapy or combination therapy, in individualizing therapy according to patient risk
  • Implement collaborative care in management of patients with PAH


Michael J. Cuttica MD, MS
Associate Professor of Medicine
Director, Northwestern Pulmonary Hypertension Program
Northwestern University Feinberg School of Medicine
Chicago, IL



Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.0 contact hour (0.1 CEU) of continuing pharmacy education credits for participating in this activity.

ACPE UAN: 0473-9999-18-009-H01-P

Activity type: Knowleddge-based

For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CE information including target audience, learning objectives, and disclosures.
  2. Review each episode.
  3. Complete the Post Test, Evaluation, and Credit Application Form.
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. The information that you participated will be uploaded to CPEMonitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit


Disclosure of Conflicts of Interest

In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.

Dr. Michael Cuttica, MD has relevant financial relationships with the following commercial interests:
Advisory Board: Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics, Bayer
Consultant: Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics, Bayer
Research Support: Actelion Pharmaceuticals, Reatta Pharmaceuticals,  United Therapeutics
Speakers Bureau: Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics, Bayer

Dr. Cuttica does not discuss any off-label uses.

No other speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2018-2019 Vemco MedEd, LLC. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support

This activity is supported by an educational grant from Actelion Pharmaceuticals.

By clicking below, I acknowledge that I have read the entire CE information.